VNRX

SEC source: 0001078782-20-000558 · primary_doc.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,828

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001078782-20-000367 · primary_doc.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,126,273

F1 · shares: The shares were purchased by the reporting person in connection with an underwritten public offering by the Issuer. The offering closed on May 22, 2020. The reported sale price reflects the price at which the reporting person purchased the shares from the underwriter.

SEC source: 0001078782-20-000271 · primary_doc.xml · derivative · entry 1

Barnes Phillip · CIK 0001790293 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 15,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000270 · primary_doc.xml · derivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 25,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000269 · primary_doc.xml · derivative · entry 1

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 30,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000268 · primary_doc.xml · nonDerivative · entry 1

Futcher Edward · CIK 0001222623 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,250

F1 · shares: Dr. Futcher received restricted stock units subject to a 2-year vesting schedule, vesting as to 5,625 units on each of 04/13/21 and 04/13/22, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001078782-20-000267 · primary_doc.xml · derivative · entry 2

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2026-04-13

F2 · derivative.exercise_date: A total of 5,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan to the reporting person's wife. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000267 · primary_doc.xml · derivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 55,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000266 · primary_doc.xml · derivative · entry 1

Kway Jasmine · CIK 0001808135 · CEO-Singapore Volition

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 55,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000265 · primary_doc.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 55,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000264 · primary_doc.xml · derivative · entry 1

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 60,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000263 · primary_doc.xml · derivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 70,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000262 · primary_doc.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 70,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-20-000261 · primary_doc.xml · derivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 85,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001477932-21-006596 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

SEC source: 0001477932-21-006595 · form4.xml · derivative · entry 3

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 70,000 shares

Expires 2026-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

SEC source: 0001477932-21-006594 · form4.xml · derivative · entry 3

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 70,000 shares

Expires 2026-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

SEC source: 0001078782-20-000141 · primary_doc.xml · derivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires 2023-02-26

F1 · balance_after: The vesting criteria of the one remaining installment of a Warrant originally granted to the reporting person on March 20, 2013, as amended, was deemed met pursuant to approval of the Compensation Committee of the Issuer effective February 26, 2020, resulting in vesting of the Warrant as to 125,000 shares effective February 26, 2020. The vested shares shall expire three years after the vesting date.

SEC source: 0001078782-20-000012 · primary_doc.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · kind: The reported transaction, consisting of the Issuer's repurchase of shares of common stock from the Reporting Person, was approved by the compensation committee of the Board of Directors (comprised of three "non-employee directors") and, pursuant to Rule 16b-3(e), is exempted from matching for purposes of Section 16(b) of the Exchange Act.

F1 · shares: The reported transaction, consisting of the Issuer's repurchase of shares of common stock from the Reporting Person, was approved by the compensation committee of the Board of Directors (comprised of three "non-employee directors") and, pursuant to Rule 16b-3(e), is exempted from matching for purposes of Section 16(b) of the Exchange Act.

SEC source: 0001078782-19-000926 · primary_doc.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on March 30, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001078782-19-000926 · primary_doc.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on March 30, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001078782-19-000927 · primary_doc.xml · derivative · entry 2

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 66,533 shares

Expires 2023-04-10

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 10, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001078782-19-000927 · primary_doc.xml · derivative · entry 1

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,467

Underlying: Common Stock · 100,000 shares

Expires 2023-04-10

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 10, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001078782-19-000925 · primary_doc.xml · derivative · entry 2

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 66,533 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on March 30, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001078782-19-000925 · primary_doc.xml · derivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,467

Underlying: Common Stock · 100,000 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on March 30, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001078782-19-000924 · primary_doc.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 66,533 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on March 30, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001078782-19-000924 · primary_doc.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,467

Underlying: Common Stock · 70,000 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on March 30, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

SEC source: 0001477932-21-006596 · form4.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

SEC source: 0001477932-21-006595 · form4.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,533 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

SEC source: 0001477932-21-006594 · form4.xml · derivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,533 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

SEC source: 0001078782-19-000892 · primary_doc.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,122,273

SEC source: 0001078782-19-000778 · primary_doc.xml · nonDerivative · entry 1

Eight Corp Ltd · CIK 0001762625 · 10% owner

Cotterford Co Ltd · CIK 0001761462 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cotterford Company Limited

Disclosed balance after: 11,706,913

F1 · kind: The reporting person's purchase of Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 46,238 shares, with the reporting person's sale of 46,238 shares of Issuer's common stock at a price of $6.0295 per share on September 27, 2019. The reporting person has paid to Issuer $15,633.07, representing the full amount of the profit realized in connection with the short-swing transaction.

F2 · ownership.nature: The securities are owned by Cotterford Company Limited ("Cotterford"). Eight Corporation Limited ("ECL") serves as the sole director of Cotterford, holds dispositive and voting control over the securities of the issuer owned by Cotterford, and may be deemed to have indirect beneficial ownership of the securities of the issuer held by Cotterford. ECL owns no securities of the issuer directly and disclaims beneficial ownership of such securities owned by Cotterford, except to the extent of its pecuniary interest therein.

SEC source: 0001078782-19-000742 · primary_doc.xml · nonDerivative · entry 1

Eight Corp Ltd · CIK 0001762625 · 10% owner

Cotterford Co Ltd · CIK 0001761462 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cotterford Company Limited

Disclosed balance after: 11,656,913

F1 · ownership.nature: The securities are owned by Cotterford Company Limited ("Cotterford"). Eight Corporation Limited ("ECL") serves as the sole director of Cotterford, holds dispositive and voting control over the securities of the issuer owned by Cotterford, and may be deemed to have indirect beneficial ownership of the securities of the issuer held by Cotterford. ECL owns no securities of the issuer directly and disclaims beneficial ownership of such securities owned by Cotterford, except to the extent of its pecuniary interest therein.

SEC source: 0001078782-19-000687 · primary_doc.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,561,284

SEC source: 0001078782-19-000676 · primary_doc.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,551,284

SEC source: 0001078782-19-000557 · primary_doc.xml · derivative · entry 2

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires not disclosed

F1 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The replacement warrant amends the performance criteria for the remaining vesting milestones.

F2 · derivative.exercise_date: The date exercisable is variable and depends on the achievement of the performance criteria outlined in the warrant agreement, as amended.

F3 · derivative.expiration_date: The subject warrant shall expire three years after the vesting date.

SEC source: 0001078782-19-000557 · primary_doc.xml · derivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires not disclosed

F1 · kind: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The replacement warrant amends the performance criteria for the remaining vesting milestones.

F2 · derivative.exercise_date: The date exercisable is variable and depends on the achievement of the performance criteria outlined in the warrant agreement, as amended.

F3 · derivative.expiration_date: The subject warrant shall expire three years after the vesting date.

SEC source: 0001078782-19-000517 · primary_doc.xml · nonDerivative · entry 2

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,501,284

SEC source: 0001078782-19-000517 · primary_doc.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,491,284

SEC source: 0001078782-19-000506 · primary_doc.xml · nonDerivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,422,015

SEC source: 0001078782-19-000187 · primary_doc.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Wife

Disclosed balance after: 0

Underlying: Common Stock · 11,000 shares

Expires 2019-02-26

F1 · ownership.nature: The Reporting Person's wife exercised a warrant to purchase 11,000 shares of Common Stock of the issuer for $2.20 per share. The warrant was set to expire pursuant to its terms on February 26, 2019.

SEC source: 0001078782-19-000187 · primary_doc.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Wife

Disclosed balance after: 22,000

F1 · ownership.nature: The Reporting Person's wife exercised a warrant to purchase 11,000 shares of Common Stock of the issuer for $2.20 per share. The warrant was set to expire pursuant to its terms on February 26, 2019.

SEC source: 0001078782-19-000130 · primary_doc.xml · derivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 50,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-19-000129 · primary_doc.xml · derivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 50,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-19-000134 · primary_doc.xml · derivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 25,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-19-000133 · primary_doc.xml · derivative · entry 1

Skaff Habib · CIK 0001620124 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 15,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-19-000132 · primary_doc.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 50,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-19-000131 · primary_doc.xml · derivative · entry 1

Futcher Edward · CIK 0001222623 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 15,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-19-000128 · primary_doc.xml · derivative · entry 1

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 50,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

SEC source: 0001078782-19-000127 · primary_doc.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · derivative.exercise_date: A total of 50,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.